RT @Neurology_Ther: Just Published: Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolera…
RT @ScienceofPD: Results from a Phase I clinical study of @pfizer's dopamine D1/D5 agonist PF-06649751 suggest that it's safe & well tolera…
Results from a Phase I clinical study of @pfizer's dopamine D1/D5 agonist PF-06649751 suggest that it's safe & well tolerated, meriting ' further study in larger clinical trials'. We are assuming this is the partial D1 agonist mentioned in the Cerevel
RT @Neurology_Ther: Just Published: Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolera…
Just Published: Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated #Parkinsonsdisease Read the full article here: https://t.co/qZnvpz4m0M https://t.co/zYBgoCNQAf